BACE1 and Alzheimer disease: Clinical efforts to reduce Aβ production in AD patients have focused on inhibitors of BACE or the γ-secretase complex, but recent trials were halted when it was found that γ-secretase inhibitors (GSI) exacerbate AD progression [7].